MedPath

Immuron Ltd.

Immuron Ltd. logo
🇦🇺Australia
Ownership
Public
Established
1994-01-01
Employees
1
Market Cap
-
Website
http://www.immuron.com

Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model

Phase 2
Active, not recruiting
Conditions
Diarrhea
Infectious Diarrhea
Travelers Diarrhea
Interventions
Other: Placebo
First Posted Date
2023-07-06
Last Posted Date
2025-05-07
Lead Sponsor
Immuron Ltd.
Target Recruit Count
60
Registration Number
NCT05933525
Locations
🇺🇸

Pharmaron Clinical Pharmacology Center, Baltimore, Maryland, United States

Treatment for Clostridium-difficile Infection With IMM529

Phase 1
Terminated
Conditions
Clostridium Difficile Infection Recurrence
Clostridium Difficile Infection
Interventions
Biological: IMM-529
Other: Placebo
First Posted Date
2017-02-27
Last Posted Date
2019-12-26
Lead Sponsor
Immuron Ltd.
Target Recruit Count
9
Registration Number
NCT03065374
Locations
🇮🇱

Hadassah Medical Center, Jerusalem, Israel

🇮🇱

Sheba Hospital, Tel HaShomer, Israel

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Phase 2
Completed
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Biological: IMM-124E
Other: Placebo
First Posted Date
2014-12-15
Last Posted Date
2020-02-21
Lead Sponsor
Immuron Ltd.
Target Recruit Count
133
Registration Number
NCT02316717
Locations
🇺🇸

University of California San Diego, San Diego, California, United States

🇺🇸

University of Colorado, Aurora, Colorado, United States

🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 22 locations

Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis

Phase 2
Withdrawn
Conditions
Nonalcoholic Steatohepatitis
Interventions
Biological: IMM 124-E
Biological: Placebo
First Posted Date
2011-11-08
Last Posted Date
2012-12-06
Lead Sponsor
Immuron Ltd.
Registration Number
NCT01466894
© Copyright 2025. All Rights Reserved by MedPath